Irene Garcia-Fogeda<sup>1</sup>, Hajar Besbassi<sup>1</sup>, Ynke Lariviere<sup>2,3</sup>, Benson Ogunjimi<sup>4,5,6</sup>, Steven Abrams<sup>2,7</sup>, Niel Hens<sup>1,7</sup>

Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium
 Global Health Institute (GHI), Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium
 Centre for the Evaluation of Vaccination, Vaccine Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium
 Antwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), Antwerp, Belgium
 Antwerp Center for Translational Immunology and Virology (ACTIV), Vaccine Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium

<sup>6</sup> Department of Paediatrics, University Hospital Antwerp, Antwerp, Belgium

<sup>7</sup> Data Science Institute (DSI), Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), UHasselt, Hasselt, Belgium

## Background

Understanding the mechanisms of within-host kinetics of the humoral (and cellular) immune response to a viral, parasite, or bacterial infection is crucial to foresee better surveillance and intervention strategies in the context of infectious diseases.

Uninfected cells Infected cells Virusinduced cell death , δ

Virus production, α

Virus Virus

tion strategies in the context of infectious diseases.

Figure 1: Flow describing the dynamics of uninfected cells, infected cells, and infectious virus

# Objectives





Fig. 2: Classification of the within-host mathematical models


- To find within-host mechanistic modeling to study humoral immunity processes after vaccination or natural infection. This is crucial to unravel the specific components of the immune system and their dynamics.
- Describe the underlying dynamics of immune cells when encountering a pathogen, and how these processes can lead to an **individual-specific response**.

# Methodology




# Results

To date, only 20 publications out of 77 have relied on mechanistic models to study the dynamics of humoral immunity.



# Contact information






# How can Bayesian methods be applied in the parameter estimation of such models?

#### Vaccine-induced setting: Berbers et al., [4]

Estimation of the model parameters and prediction of the **peak antibody concentrations together with half-time antibody values** were performed using Hierarchical Bayesian methods and Monte Carlo Markov Chain (MCMC).

- Simple exponential decay
- Parametric distributions
  for the antibody growth and
  decay (e.g., Gamma, Inverse
  gamma).



# Natural infection setting: White et al., [1]

White et al., [1] studied the impact of maternal immunity on Malaria infections in children.

MCMC iteration using a random walk Metropolis-Hastings algorithm (Model 1):

- 1. Local parameter (n)
  - $\vec{\theta^{n'}} = [d_m^{n'}, d_a^{n'}, A_m^n, \theta_1^n ... \theta_N^n]$
  - $L_{mix}^{n}(\theta_{n}'|D_{n})$
  - Accept probability  $min = \left\{1, \frac{L_{mix}^n(\theta_n'|D_n)}{L_{mix}^n(\theta_n|D_n)}\right\}$
- 2. Nuisance parameter (n)
  - $\vec{\theta^{n'}} = [d_m^n, d_a^n, A_m^{n'}, \theta_1^{n'}...\theta_N^{n'}]$
  - $L_{mix}^{n}(\theta_{n}'|D_{n})$
  - Accept probability  $min = \left\{1, \frac{L_{mix}^n(\theta_n'|D_n)}{L_{mix}^n(\theta_n|D_n)}\right\}$
- 3. Global parameter
  - $\vec{\theta} = [d_m', d_a', \sigma_m', \sigma_a', \sigma_{obs}', \theta^1 ... \theta^N]$
  - Calculate the total likelihood  $L_{TOTAL}(\theta'|D_n)$  and update the prior  $P(\theta')$
  - Accept probability  $min = \left\{1, \frac{L_{TOTAL}(\theta'|D) * P(\theta')}{L_{TOTAL}(\theta|D) * P(\theta)}\right\}$

Truncated normally distributed measurement error 200 million MCMC iterations computed with acceptance rates using Robins-Munro algorithm.

#### Natural infection setting: Teunis et al., [5]

Teunis et al, [5] extended the work by de Graaf et al., [6] defining multiple antibody production sites defined as  $c_k$  below.

Infection and waning immunity process respectively

$$b'(t) = \mu_0 * b(t) - \sum c_k * y_k(t)$$

$$y'_k(t) = \mu_k * y_k(t)$$

$$b(t) = 0$$

$$y'_k(t) = -w_k^* * y_k(t)$$

What functions are studied? | Non-exponential decay | Bi-exponential decay | Power functions

All models used 3 chains and  $10^6$  iterations. A multivariate normal prior was chosen for the different model parameters, and a Wishart distribution for the random effects.

#### References

- [1] White, M. T., Griffin, J. T., Akpogheneta, O., Conway, D. J., Koram, K. A., Riley, E. M., Ghani, A. C. (2014). Dynamics of the antibody response to Plasmodium falciparum infection in African children. The Journal of infectious diseases, 210(7), 1115–1122. https://doi.org/10.1093/infdis/jiu219
- [2] Gelman, A., Hwang, J., and Vehtari, A. (2013). Understanding predictive information criteria for Bayesian models. Statistics and Computing
- [3] Handel, A., Brown, J., Stallknecht, D., Rohani, P. (2013). A multi-scale analysis of influenza A virus fitness trade-offs due to temperature-dependent virus persistence. PLoS computational biology, 9(3), e1002989. https://doi.org/10.1371/journal.pcbi.1002989
- [4] Berbers, G. A., van de Wetering, M. S., van Gageldonk, P. G., Schellekens, J. F., Versteegh, F. G., and Teunis, P. F. (2013). A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens. Vaccine, 31(36), 3732–3738. https://doi.org/10.1016/j.vaccine.2013.05.073
   [5] Teunis, P. F., van Eijkeren, J. C., de Graaf, W. F., Marinovi´c, A. B., Kretzschmar, M. E. (2016). Linking the seroresponse to infection to within-host heterogeneity in
- antibody production. Epidemics, 16, 33–39. https://doi.org/10.1016/j.epidem.2016.04.001

  [6] de Graaf, W. F., Kretzschmar, M. E., Teunis, P. F., and Diekmann, O. (2014). A two-phase within-host model for immune response and its application to serological profiles of pertussis. Epidemics, 9, 1–7.

#### Findings

#### 1. COMPARTMENTS

- Data-driven approaches: Typically study the interaction between pathogen growth with antibody production, or the dynamics between short- and long-living cells with antibodies.
- Theory-driven approaches: Typically study more complicated processes, starting from susceptible cells population to neutralizing antibody production.

#### 2. PARAMETERS

- Data-driven approaches: Linear, non-linear mixed approaches. Exponential decay, bi-exponential, power functions. Smoothing functions and binary functions represent normally the time of vaccination.
- Theory-driven approaches: Simulation approaches to generate the parameters (e.g., Poisson or Binomial distributions).

#### 3. INFERENCE/ANALYTICAL ANALYSES

- Data-driven approaches: Use of Maximum likelihood estimation (MLE) and Bayesian hierarchical approaches with Monte Carlo Markov Chain (MCMC).
- Theory-driven approaches: Model's equilibria and stability.

#### 4. COVARIATES

Study groups are widely studied. However, there is a lack of information on geographical background, surveillance systems, and age.

### 5. MODEL COMPARISON

- Data-driven approaches: Difficulties in Bayesian approaches due to the number of parameters and complexity issues. WAIC (Watanabe-Akaike information criteria) for future modelling work AIC (Akaike information criteria) within MLE [2].
- Theory-driven approaches: Comparison to simulated data.

## Conclusion

- More research is needed on the **methods of inference** in data-driven mechanistic models, such as semi-parametric to full parametric tools.
- Biological mechanisms must be distinguished in vaccination or natural infection settings.

# Acknowledgments

IGF and NH acknowledge support from the EBOVAC3 project which has received funding from the IMI2 Joint Undertaking under grant agreement No 800176 (IMI-EU). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme, European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Coalition for Epidemic Preparedness Innovations (CEPI).



